Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer
NCT02204098Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2015
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of mammaglobin-A DNA vaccine in breast cancer (4 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Number of participants who experience an adverse event at Day 126. Started Jan 2015; status: active, not recruiting.
02
Drugs
mammaglobin-A DNA vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02204098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204098.